Circulating tumor cell (CTC) detection is a form of liquid biopsy that captures and analyzes cancer cells that have broken away from a tumor and entered the bloodstream. These cells are extraordinarily rare, sometimes just a handful among billions of normal blood cells, yet they are believed to be the primary drivers of metastasis. Detecting and studying them from a simple blood draw, rather than an invasive tissue biopsy, has become one of the more promising frontiers in cancer diagnostics and monitoring.
What Circulating Tumor Cells Actually Are
Tumor cells can shed from a primary tumor, enter the blood, and travel to distant organs where they may seed new tumors. These traveling cells are what researchers call circulating tumor cells.1PubMed Central. The biology and clinical potential of circulating tumor cells The journey from shedding to colonization is not simple. CTCs interact with immune cells, platelets, and the lining of blood vessels along the way, and they undergo changes in their surface features and behavior that help some of them survive.
One of the more dangerous survival strategies involves platelets. When a CTC enters the bloodstream, activated platelets can rapidly stick to it and form a protective shell. This coating of platelets, essentially a tiny clot wrapped around the cancer cell, shields the CTC from immune cells like natural killer cells and helps it latch onto blood vessel walls.2PubMed Central. The role of platelets in tumor immune evasion and metastasis: mechanisms and therapeutic implications The platelet barrier also protects against the physical shear forces of blood flow that would otherwise destroy many loose cells.
Most CTCs do not survive this gauntlet. The vast majority die in circulation, destroyed by immune attack, mechanical stress, or an inability to adapt to the hostile bloodstream environment. But the tiny fraction that do survive can be enough to establish metastatic disease, which is why detecting them matters so much.
How CTC Detection Works
The fundamental challenge is rarity. A patient with advanced cancer might have only a few CTCs per milliliter of blood, surrounded by millions of white blood cells and billions of red blood cells. Finding them requires either targeting something specific on their surface or exploiting a physical difference between cancer cells and normal blood cells.
The most established approach is antibody-based capture, which uses antibodies designed to grab onto a protein called EpCAM that sits on the surface of many epithelial cancer cells. The CellSearch system, which is the only CTC detection platform with FDA clearance, works this way. A blood sample is mixed with tiny magnetic beads coated in anti-EpCAM antibodies. The beads latch onto any EpCAM-positive cells, and a magnet pulls those cells out of the sample for identification. However, different antibodies targeting EpCAM can produce inconsistent results even in the same patient’s blood. A study using two different EpCAM antibodies on blood from patients with colorectal cancer found that detection varied depending on which antibody was used.3PubMed Central. Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies
An entirely different family of methods skips the antibody step altogether. These label-free approaches separate CTCs from other blood cells based on physical traits like size, stiffness, or density. Cancer cells tend to be larger and less flexible than white blood cells, and microfluidic devices can exploit those differences. One platform, the Parsortix system, pushes blood through tiny channels that trap cells based on their size and how easily they deform.4PubMed Central. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells Another approach uses oscillating flow through tapered constrictions to create different paths for CTCs, white blood cells, and red blood cells, separating them by stiffness even when cell sizes are almost identical.5PubMed. Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic Ratchets Sound waves have also entered the picture, with microfluidic devices that use alternating acoustic fields to push cells of different sizes and compressibility into separate channels.6PubMed Central. Label-Free Separation of Circulating Tumor Cells and Clusters by Alternating Frequency Acoustic Field in a Microfluidic Chip
There are even experimental methods that work inside the body rather than on a drawn blood sample. One concept uses a surface-modified needle inserted into a vein during a standard transfusion. As blood flows past the needle, CTCs stick to its coated surface and can be collected afterward. This approach has been tested in animal models with promising capture rates.7PubMed. In Vivo Capture of Circulating Tumor Cells Based on Transfusion with a Vein Indwelling Needle
The Problem with Relying on EpCAM Alone
Once cells are captured, they still need to be confirmed as cancer cells. The standard method stains them for cytokeratin (a marker found on epithelial cells, including most cancer cells) and checks for the absence of CD45 (a marker found on white blood cells). A cell that is cytokeratin-positive and CD45-negative is flagged as a likely CTC.8PubMed. Minimizing false positives for CTC identification But there is a deeper issue with detection methods that rely on EpCAM.
When cancer cells prepare to leave a tumor and spread, many of them go through a process that changes their character from epithelial (sticky, stationary) to mesenchymal (mobile, invasive). During this shift, cells can lose or dramatically reduce their EpCAM expression. Research on breast cancer CTCs showed that cells maintained in conditions that push them toward a more mesenchymal state had sharply reduced EpCAM levels, along with smaller size and lower mass.9PubMed Central. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer When the same researchers isolated CTCs from breast cancer patients using a label-free device, they found that the cells had widely varying EpCAM levels, suggesting that EpCAM-dependent methods could be undercounting CTCs and missing important subgroups.
This is not a theoretical concern. A separate study found that when a commercial EpCAM-based detection test failed to find CTCs, the missed cells had downregulated EpCAM while gaining mesenchymal markers like Twist.10PubMed Central. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition The cells most likely to be missed, in other words, may be the ones furthest along in the process of becoming metastatic. This is one reason why label-free methods are attracting so much research interest: they do not care whether a cell expresses EpCAM, so they stand a better chance of capturing the full diversity of CTCs.
CTC Clusters and Why They Matter
For a long time, researchers imagined metastasis as a solo act: one cell breaks free, floats through the blood, and lodges in a distant organ. That picture is incomplete. Improved detection has revealed that CTCs sometimes travel in groups, called CTC clusters, and these clusters are far more dangerous than lone cells. Estimates suggest clusters have somewhere between 20 and 100 times the metastatic potential of a single CTC.11PubMed Central. Better together: circulating tumor cell clustering in metastatic cancer
The advantage of traveling together appears to come from several factors. Cells in a cluster can hold each other together with adhesion proteins and tight-junction molecules, which helps them survive the mechanical stress of circulation. Clusters also seem better at evading immune detection and may contain a mix of cell types, some of which are not cancer cells at all but rather immune cells or platelets that get swept up in the group.12PubMed Central. Circulating tumor cell clusters: What we know and what we expect Because clusters are larger and less flexible than single cells, they also present a different engineering challenge for detection platforms. Methods designed to capture single cells can break apart or miss clusters entirely, which means detection technology has to be designed with clustering in mind.
What CTC Counts Tell Doctors
The most straightforward clinical use of CTC detection today is as a prognostic marker. In metastatic colorectal cancer, patients whose baseline CTC counts were above an unfavorable threshold had substantially shorter survival. One study found that those with unfavorable counts lived a median of about 9 months, compared to roughly 21 months for patients with favorable counts.13PubMed. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer Similar patterns have been documented in breast, prostate, and gastric cancers.
Beyond a snapshot at diagnosis, tracking CTC numbers over time during treatment adds another layer of information. In advanced gastric cancer, patients whose CTC counts stayed favorable or converted from unfavorable to favorable during therapy had markedly longer progression-free and overall survival compared to those whose counts stayed high or worsened. The group whose numbers stayed favorable had a median progression-free survival of about 8 months, while the group whose counts worsened came in around 3 months.14British Journal of Cancer. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer A pilot study in rectal cancer also found that CTC changes during treatment appeared to reflect how well therapy was working, raising the possibility of using CTC trends as an outcome measure in clinical trials.15PubMed. Monitoring Treatment Response in Rectal Cancer through Circulating Tumor Cell Dynamics: A Pilot Clinical Study
The practical appeal is clear: instead of waiting weeks for an imaging scan to show whether a tumor has shrunk, a blood test could give an early signal that treatment is or is not working. That said, CTC counting is not yet used to make treatment decisions in routine practice. It remains a prognostic tool that adds context alongside imaging and other tests.
Reading the Genetic Fingerprint of Individual CTCs
Counting CTCs is useful, but the real frontier is figuring out what is going on inside them. Techniques now allow researchers to sequence the DNA or RNA of individual captured cells. In one study of metastatic breast cancer, sequencing individual CTCs for 50 cancer-related genes revealed more than 50 distinct sequence variants across 25 genes, with significant differences both between patients and between CTCs from the same patient.16PubMed Central. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer That kind of cell-to-cell variation is exactly what makes cancer so hard to treat: a tumor is not one uniform mass but a collection of genetically distinct subclones, and CTCs reflect that diversity.
Single-cell RNA sequencing takes this further by revealing which genes are active in each CTC, not just what mutations they carry. This can help researchers identify distinct CTC subtypes, understand how cancer cells interact with their environment, and potentially find new therapeutic targets.17PubMed Central. Single-cell RNA-sequencing of circulating tumour cells: A practical guide to workflow and translational applications In a study of pediatric neuroblastoma, single-cell sequencing of CTCs identified specific gene amplifications and mutations that matched the primary tumor, along with activation of genes related to blood vessel formation and cell division. Some patients’ CTCs even divided into genetically distinct subgroups.18PubMed Central. Single-cell next-generation sequencing of circulating tumor cells in patients with neuroblastoma
The long-term vision is personalized treatment selection. If you can capture a patient’s CTCs, read their mutations, and test drugs against them, you might be able to choose the right therapy without an invasive biopsy and repeat the process whenever the cancer evolves.
CTCs Compared to Other Liquid Biopsy Targets
CTCs are not the only thing in blood that reveals information about a tumor. Circulating tumor DNA (ctDNA), tiny fragments of DNA shed by dying tumor cells, and extracellular vesicles (small membrane-enclosed packages released by cells) are two other major liquid biopsy targets. Each captures different aspects of cancer biology.
CTCs are intact living cells. They can be grown in culture, their genes can be read, and their physical properties can be studied. ctDNA, by contrast, is debris from dead cells. It is easier to detect in larger quantities but reflects a tumor’s genetic makeup without providing a living cell to study. Research in metastatic breast cancer found that CTC counts and ctDNA levels offered complementary rather than redundant information, with CTC numbers reflecting tumor biology and ctDNA better tracking the total amount of tumor in the body and how it responds to treatment.19PubMed Central. Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer A review of liquid biopsy in colorectal cancer reached a similar conclusion, noting that CTCs and ctDNA are released at different rates depending on tumor type and stage, and that using both provides a more complete picture than either alone.20PubMed Central. Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons
Extracellular vesicles, including exosomes, represent yet another window. These tiny packages carry proteins, RNA, and DNA from their parent cells and can be found in much higher numbers than CTCs. They are easier to collect in bulk, which makes certain analyses more practical, but they are not living cells and cannot be grown or functionally tested the way CTCs can.21PubMed Central. Exosome-based liquid biopsies in cancer: opportunities and challenges One review described the distinction neatly: CTCs are “living material eventually recoverable,” while extracellular vesicles are essentially dead material with temporary effects on the cells they reach.22PubMed Central. Extracellular Vesicles and Circulating Tumour Cells – complementary liquid biopsies or standalone concepts? The emerging consensus is that the best liquid biopsy strategy will likely use multiple analytes together rather than relying on any one of them.
Growing Living Tumor Models from CTCs
One of the most exciting extensions of CTC detection is the ability to take captured cells and grow them into three-dimensional structures called organoids. These miniature tumor models, grown in the lab from a patient’s own CTCs, can recapitulate some of the biology of the original cancer and be used to test drugs before giving them to the patient.23PubMed Central. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine
In colorectal cancer, researchers grew organoids from captured CTCs and compared them to organoids grown from tumor tissue obtained through traditional means. The CTC-derived organoids showed higher migratory and invasive behavior and responded differently to certain drugs. They were particularly sensitive to compounds targeting the Survivin pathway, a finding that did not emerge from the tissue-derived organoids.24PubMed Central. An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile That difference matters because CTCs may more closely represent the cells that actually spread cancer, meaning drug sensitivity data from CTC-derived organoids could be more clinically relevant than data from the original tumor mass.
The practical barrier is efficiency. Growing organoids from CTCs requires capturing enough viable cells, which is hard when counts are low. And not all captured CTCs will successfully form organoids. But when it works, you get a renewable, patient-specific model of the most dangerous cells in a cancer.
Why Standardization Remains a Major Hurdle
For all its promise, CTC detection still faces a fundamental problem: there is no universally agreed-upon way to do it. Different platforms use different capture methods, different antibodies, different physical cutoffs, and different criteria for what counts as a confirmed CTC. A comprehensive review of CTC assessment methods found that standardization across the field is insufficient, making it difficult to compare results between studies and limiting the ability to translate research findings into clinical practice.25PubMed. Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials
This matters because a CTC count from one platform cannot necessarily be compared to a count from another. A patient tested with CellSearch might get one number, while the same blood sample run through a microfluidic device might yield a different count, potentially capturing different subpopulations of cells. For CTC detection to become a standard clinical tool on par with imaging or blood chemistry panels, the field needs agreed-upon protocols for sample handling, cell capture, identification criteria, and reporting formats. Until that happens, much of the CTC data produced in research settings stays in research settings.
CTCs Follow a Circadian Rhythm
An unexpected finding that could influence how CTC detection is performed in practice is that CTC numbers in the blood are not constant throughout the day. In an animal model using in vivo flow cytometry, researchers discovered that CTC counts showed clear daily oscillations, peaking in the evening and dropping to a low point in the morning. The rhythm persisted even in constant darkness, confirming it was driven by the body’s internal clock rather than just the light-dark cycle, though light did act as the signal that kept the rhythm synchronized.26Light: Science & Applications. In vivo flow cytometry reveals a circadian rhythm of circulating tumor cells
If this circadian pattern holds in humans, it means the time of day a blood sample is drawn could significantly affect the CTC count. A morning draw might produce a falsely low number, while an evening draw might catch more cells. This has not yet been confirmed in human clinical studies, but it is the kind of variable that standardization efforts will eventually need to address. It also raises broader biological questions about why tumor cell shedding follows a daily pattern, and whether the timing of metastasis itself is influenced by the circadian clock.